Atlas Trials

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers

Clinical trial NCT06169579 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT06169579
Sponsor
Shenzhen NewDEL Biotech, Co., Ltd
Status
ENROLLING_BY_INVITATION
Phase
Phase 1
Study type
INTERVENTIONAL
Advanced Solid Tumor
Start date
2024-02-04
Primary completion
2025-12-01
Enrollment
96

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.